TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 3 year overall survival
Endpoint domain: Mortality/survival
Primary endpoint: 3 year relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Mentalizing/Theory of Mind
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rehospitalization for heart failure (HF)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Anorectal perception thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of specific drug use
Endpoint domain: Adverse events/effects
Primary endpoint: percent parents for receiving help for Family Stressors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: rates of child maltreatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of harsh punishment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: percent reporting child behavior problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rate of atypical child development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak-to-peak amplitudes of dermatomal somatosensory evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Assessment of reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oral motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Achieving at Least a 50% Reduction in SALT Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Area Under the Curve Over 24 Hours (AUC24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Disease Activity Score in 28 Joints (DAS28-4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Ocular Discomfort Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first voiding after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to first voiding after catheter removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in total shoulder outcome scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year event-free survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: Serum IGF1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in the rate of cervical cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immunogenicity profiles for influenza virus vaccine strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of FAS response to glucose changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and performance of FAS response
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease of serum levels of luteinizing hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decrease of serum levels of Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decrease of serum levels of FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Per-operative evaluation of the rectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Cuff pressure after position change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety Endpoints
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients exceeding preoperative opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Achieving 75% Improvement in PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline in very long chain fatty acid (VLCFA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants on TCZ SC
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinically Notable Pulse Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinically Notable Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinically Notable Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinically Notable QTc Interval Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum Potassium (mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Glucose (mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Distribution volume of [11C]donepezil in internal organs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Appearance As Assessed by the Patient and Observer Scar Assessment (POSAS) Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenoma Recurrence Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sustained Virologic Response at 24 Weeks After Treatment Discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Eczema Area and Severity Index (EASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Eczema Area and Severity Index (EASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulmonary compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Non-Serious Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance over systemic availability (Cl/F) during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC0-24 for efavirenz, AUC0-12 for nevirapine) during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum plasma drug concentration (Cmin) during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrocardiogram (ECGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Disease Relapse
Endpoint domain: Mortality/survival
Primary endpoint: Completion of Paper Chart
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Knowledge of kick counting post delivery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clear-headedness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Remission after 8 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of DBS Leads With Clinical Programming Consistent With Predictions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from Baseline Hamilton Depression Rating Scale (HDRS) at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of complete response after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fold-Change in Epidermal Thickness of Lesional Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in detection of colorectal adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of intraoperative time with a decrease of cerebral regional oxygen saturation (SrO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hospitalizations with any hypersensitivity reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Type 1 Diabetes Status Overall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of blockage - accumulation of biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in targeted clinical laboratory test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator-assessed confirmed objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in progression of Thyroid Associated Ophthalmopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal esophageal distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Conditioned fear as assessed by skin conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety as assessed by the Spielberg Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Experimental Pain as assessed by a pain rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mindfulness Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PEG Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS Sleep-Related Impairment
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Generalized Anxiety Disorder 7 (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percent cells with positive UCHL1 staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in memory score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with SIRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in left ventricular enddiastolic volume index (LVEDVi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunogenicity of vaccine against WN virus
Endpoint domain: Physiological/clinical
Primary endpoint: Rate of Patient Reported Experienced Measures (PREM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Birthweight centile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of target vessel failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: In-scaffold late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Glycosylated Hemoglobin (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Observed concentration at the end of the infusion (Ceoi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Areas Under the plasma concentration Curve (AUClast and AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calories per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total saturated fats per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Additional Diagnostic Information
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in fasting and postprandial glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in insulin levels, fasting and postprandial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Survived
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients With Refractory Hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Patients With Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Globotriaosylceramide level, plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prehospital Delay between Stroke Onset and Admission to the Hospital
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1c (HbA1c) at Month 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Dynamic Phase Secreted Insulin Per Unit of Glucose Concentration (Φd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial Glycaemic Response Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Technical feasibility of the Serranator™ Alto PTA Serration Balloon Catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Self-efficacy and decrease in psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of attendance to on-demand follow up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 6 Minute Walk Test (6MWT) distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: catheter associated bloodstream infection (BSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with AEs leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Abductor strength measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of complete wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Repetition of bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Immune response in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response in PBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response in tumor DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Histological Sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological Sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Nonmotor Symptoms Scale (NMSS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of pulmonary vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of downstaging of stage B and C Hepatocellular Carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fracture fixation complication events
Endpoint domain: Adverse events/effects
Primary endpoint: Central ventilatory control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction when awakening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: H2 elevation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of Change in UMSARS Part I Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: end point event
Endpoint domain: Mortality/survival
Primary endpoint: Changes in the Brain's Default Mode Network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of clopidogrel determined by VASP measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Positive Responses in Virus-specific Antibody in Sera
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Isotype Ratios on Day 56
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in pain density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regression of retinal neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in glucose response to 2-hour oral glucose tolerance test (OGTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Post-Prandial Glucose Excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total antioxidant capacity (TAC) in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of mitral E' velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perceived Pain Level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in Score on Perceived Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: Grade 3-4 acute graft versus host disease (aGVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CERAD-NAB scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change From Baseline in Morning Peak Expiratory Flow (PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chemotherapy-induced peripheral neuropathy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time until the start of a new antidepressant treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MRC dyspnea questionnaire results
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of aGvHD
Endpoint domain: Adverse events/effects
Primary endpoint: VAS evaluation of usual symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNOT-20 evaluates the quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of Lund-Kennedy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of titration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose level of Instanyl® after titration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of prenatal health insurance for free dental examination
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adverse event DTOX (death or autoimmune toxicity or vascular toxicity)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of ankle dorsiflexor isometric muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients with acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pulmonary diffusion level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Suicidality assessment using the Suicidality Tracking Scale (STS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of IBS-SSS Total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety laboratory assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sputum cells count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: BOLD response indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular Changes in Markers of Cell Proliferation and Apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: day time return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Adverse events - Treatment Emergent
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of Erosive Esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AEs Grade 3 or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With 1 or More Grade 3 or Higher AE
Endpoint domain: Adverse events/effects